News

News

Featured News

Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.

BIOVECTRA Welcomes Normand Blais to Senior Director, Development & Innovation, Biologics Role

January 18, 2023

BIOVECTRA is pleased to announce that Normand Blais was appointed as Senior Director, Development & Innovation, Biologics. […]

BIOVECTRA Welcomes Normand Blais to Senior Director, Development & Innovation, Biologics Role

18 January 2023

BIOVECTRA Named One of Canada’s Top Employers Again in 2023

22 November 2022

BIOVECTRA Expands Manufacturing Capacity with Single-Use Microbial Fermentation Technology

31 October 2022

BIOVECTRA Named to True North List of Leading Canadian Companies

4 July 2022

BIOVECTRA Starts Construction on its Charlottetown mRNA Biomanufacturing Centre

14 April 2022

BIOVECTRA mRNA Vaccine and Bio-manufacturing Facility Announced

18 November 2021

BIOVECTRA HONOURED TO BE NAMED ONE OF CANADA’S TOP 100 EMPLOYERS 2022

12 November 2021

BIOVECTRA ANNOUNCES APPOINTMENT OF GORDON C. MCCAULEY AND STEVEN M. KLOSK TO BOARD

21 October 2021

Biovectra Enhances Manufacturing Capacity and Flexibility with ABEC’s CSR® Large-Scale, Single-Use Microbial Fermentation Technology

20 September 2021

PhaseBio Pharmaceuticals and BIOVECTRA Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

11 March 2021

Major investment anchors alliance for bioscience skills and training in Atlantic Canada

8 June 2020

COVID-19: Our Obligation

31 March 2020

BIOVECTRA Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital

4 November 2019

Mallinckrodt Agrees to Sell BIOVECTRA Inc. to H.I.G. Capital for $250 Million

10 September 2019

BIOVECTRA Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project

7 April 2019

BIOVECTRA Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)

17 March 2019

BIOVECTRA Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities

15 March 2019

BIOVECTRA Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund

4 March 2019

BIOVECTRA wins BIOTECanada’s Gold Leaf Award for Company of the Year!

26 September 2018

BIOVECTRA and TUBE Biopharmaceuticals Sign Exclusive License for Microbial Fermentation Technology to Manufacture Tubulysins

16 July 2018

Windsor Expansion Helps BIOVECTRA Meet Global Market Demand

12 April 2018

BIOVECTRA and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion

14 December 2017

BIOVECTRA Inc. Celebrates the Opening of Flagship Warehouse & Process Development Suites as part of Global Biotech Week

21 September 2017

BIOVECTRA Inc. to Open New Microbial Fermentation and Complex Chemistry Site in December 2017

24 May 2017

Join us in New York City for DCAT Week 2017 – March 20-23

6 March 2017

DCAT Announces New Advisory Council Member

5 March 2017

BIOVECTRA Goes Global

26 February 2017

Joint Venture Contract Services – A CDMO’S Approach To Being A True Partner

20 September 2016

What makes BIOVECTRA a “Leader in today’s competitive CDMO market.”

8 June 2016

Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies

20 May 2016

BIOVECTRA – Hiring Practices – The Employment Journey on PEI

29 January 2016

BIOVECTRA Announces Acquisition of Former Sunovion (Sepracor) Facility

23 June 2014

BIOVECTRA Spending $3.8 Million on Expansion

14 June 2014

BIOVECTRA Starts Construction to Expand Charlottetown Facility

11 June 2014

Risk Management in Financing of Capital Expansions

1 May 2014

BIOVECTRA Named Agent of Reagent Proteins’ Products

25 June 2013